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Human polymorphonuclear leukocytes ad-
hesion to endothelial cells during the early
stage of inflammation leads to cell surface
externalization of Annexin A1 (AnxA1), an
effector of endogenous anti-inflammation.
The antiadhesive properties of AnxA1 be-
come operative to finely tune polymorpho-
nuclear leukocytes transmigration to the
site of inflammation. Membrane bound pro-
teinase 3 (PR3) plays a key role in this
microenvironment by cleaving the N termi-
nus bioactive domain of AnxA1. In the
present study, we generated a PR3-resistant
human recombinant AnxA1—named super-
AnxA1 (SAnxA1)—and tested its in vitro and
in vivo properties in comparison to the pa-
rental protein. SAnxA1 bound and activated
formyl peptide receptor 2 in a similar way as
the parental protein, while showing a resis-
tance to cleavage by recombinant PR3.
SAnxA1 retained anti-inflammatory activi-
ties in the murine inflamed microcirculation
(leukocyte adhesion being the readout) and
in skin trafficking model. When longer-
lasting models of inflammation were ap-
plied, SAnxA1 displayed stronger anti-
inflammatory effect over time compared
with the parental protein. Together these
results indicate that AnxA1 cleavage is an
important process during neutrophilic in-
flammation and that controlling the bal-
ance between AnxA1/PR3 activities might
represent a promising avenue for the discov-
ery of novel therapeutic approaches. (Blood.
2010;116(20):4288-4296)
Introduction
The initial phase of an inflammatory response is characterized by
the recruitment and activation of circulating polymorphonuclear
leukocytes (PMNs) to the site of inflammation. During this phase,
neutrophils egress the vascular endothelium and migrate into
peripheral tissues thanks to the coordinated action of adhesion
molecules and other mediators, including proinflammatory cyto-
kines and autacoids.1 It is now appreciated that elicitation of this
inflammatory cascade leads also the activation of counter-
regulatory pathways to contain these responses, ensuring that
resolution of inflammation takes place once the dangerous stimulus
has been disposed of.2,3 Among these effectors of resolution there is
the Annexin A1 (AnxA1)–formyl peptide receptor 2 (FPR2)
pathway, an endogenous homeostatic anti-inflammatory system4
that acts as a “brake” for PMN adhesion to the microvascular wall
preventing further cell transmigration to the inflammatory site.5
This phenomenon occurs after the externalization of the protein to
the cell surface where it binds to its cognate receptor FPR2,6 initiating a
cascade of signaling events eventually leading to rapid and late
responses, including detachment of adherent cells,7 L-selectin
shedding,8 and phagocytosis of apoptotic cells9 (reviewed in4).
In analogy with the complexity—yet tight regulation—of the
phenomena described above, the anti-inflammatory and antiadhe-
sive effects of AnxA1 are also subjected to fine modulation;
externalization of the protein on the PMN plasma membrane is
accompanied by cleavage of a unique region10 of the protein: the N
terminus.11 This region has been suggested to play a pivotal role for
anti-inflammatory properties of the full-length protein and peptides
designed on this 50-amino acid–long sequence display anti-
inflammatory and tissue-protective properties.7,12,13
The cleavage of AnxA1 N terminus occurs after PMN activa-
tion5 and has been extensively documented in vitro and in in vivo
models of inflammation, as well as in human and experimental
inflammatory exudates.14,15 However, one point yet to be addressed
is the functional relevance of AnxA1 cleavage upon PMN activa-
tion, with 2 alternative explanations: (1) AnxA1 cleavage is an
homeostatic mechanism limiting the biologic function of the
protein or (2) it is an activating step leading to the release of
bioactive N terminus–derived peptidomimetics, so that the protein
might act as a pro-drug.
We have recently addressed the issue of AnxA1 cleavage in the
context of PMN activation, reporting a central role of proteinase 3
(PR3).11 This enzyme is one of the PMN serine proteases,16 and it is
expressed both in PMN granules and membranes, contributing to
the bactericidal and proinflammatory properties of these cells. Most
interestingly, we found that PR3 colocalizes with AnxA1 after
PMN activation and it becomes responsible for cleaving the protein
at 3 discrete sites: Alanine11, Valine22, and Valine36. Thus, we
hypothesized that blocking AnxA1 cleavage by PR3 would signifi-
cantly affects its anti-inflammatory effects.
In this study, we have conducted a systematic analysis of the
functional role of these 3 cleavage sites for susceptibility to PR3.
Generation of a PR3 cleavage-resistant AnxA1 triple-mutant
(AnxA1-A11R/V22K/V36K, termed super AnxA1 or SAnxA1) was
then accomplished, together with its in vitro and in vivo biologic
characterization. We conclude that pharmacologic modulation of
AnxA1 cleavage might represent a novel therapeutic strategy to
limit excessive inflammatory responses.
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Methods
Cells
The stably transfected FPR2-HEK293 cell line was cultured as before.17
PMNs of healthy individuals were isolated by Hystopaque (Sigma-
Aldrich) sedimentation of blood collected in 3.2% sodium citrate (Sigma-
Aldrich) as described17 (experiments were approved by the Queen Mary
University of London Research Ethics Committee; P/00/029 ELCHA). For
preparation of whole cell lysates, PMNs and HEK293 cells were resus-
pended (1  108/mL and 2  106/mL, respectively) in lysis buffer (200mM
NaCl, 20mM Tris-HCl, pH 8.0, 1% Triton X-100) for 10 minutes. When
cell lysates were prepared for Western blot analysis only, a mixture of
protease and phosphatase inhibitors was added to the lysis buffers.
Mice
Female BALB/c mice (7-8 weeks) or male C57BL/6 (23-28 g; Charles
River) were kept under standard conditions and maintained in a 12-hour/
12-hour light/dark cycle at 22°C in accordance with United Kingdom Home
Office regulations (Guidance on the Operation of Animals, Scientific
Procedures Act 1986) and of the European Union directives.
Molecular and cellular analyses
Site-directed mutagenesis. AnxA1 mutants were constructed by polymer-
ase chain reaction mutagenesis using the double-tagged (c-Myc on the N
terminus, Flag on the C-terminus, MFAnxA1) human AnxA1-pcDNA3.111
as a template. All mutants were constructed using oligonucleotide-mediated
mutagenesis (QuickChange site-directed mutagenesis kit; Stratagene, Agi-
lent Technologies UK Limited) according to the manufacturer’s instruc-
tions. The single point mutations A11R, V22K, and V36K were constructed
using oligonucleotides designed with QuickChange Primer Design Pro-
gram. In addition to the single point mutations, 3 double-mutants (A11R/
V22K, A11R/V36K, V22K/V36K) and one triple-mutant (A11R/V22K/V36K)
were also constructed. The oligonucleotide primers (0.4M) were extended
by PCR (19 cycles of consisting of incubation for 20 seconds at 95°C,
30 seconds at 55°C, and 14 minutes at 68°C) and final extension
(10 minutes at 68°C) using Pfu Ultra DNA Polymerase (Promega) in
presence of 5% dimethyl sulfoxide (Sigma-Aldrich). PCR products were
digested using DpnI (New England Biolabs) at 37°C for 2 hours and
transformed into TOP10 cells (Invitrogen). The presence of each point
mutation was confirmed by plasmid DNA sequencing (Cogenix).
Transfection. MFAnxA1 and MFAnxA1 mutants constructs (2 g)
were transfected into HEK293 cells, using 6 L FuGENE6 transfection
reagent (Roche) and 92 L OptiMEM (Invitrogen) culture medium for each
well of a 6-well culture plate (containing 5  105 cells). After 24 hours,
cells from each well were lysed in 500 L lysis buffer.
Western blotting. Samples boiled in 6  Laemmli buffer were
subjected to standard sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and electrophoretically blotted onto polyvinylidene diflouride
membranes (Millipore). Membranes were incubated with primary antibod-
ies in Tris-buffered saline solution containing Tween 20 and 5% (wt/vo;)
nonfat dry milk overnight before a 1.5-hour incubation period with
horseradish peroxidase-conjugated secondary antibody (Dako). Proteins
were detected using the enhanced chemiluminescence detection kit and
visualized on Hyperfilm (Amersham Biosciences). The primary antibodies
used were rabbit polyclonal anti-AnxA1 (Zymed Laboratories, Invitrogen),
mouse monoclonal anti–c-Myc (Santa Cruz Biotechnology), mouse mono-
clonal anti-FLAG M2 (Sigma-Aldrich), and mouse monoclonal anti-
phospho Erk1/2 and anti-Erk1/2 (Santa Cruz Biotechnology).
AnxA1 cleavage assay. All extracts used in the cleavage assay were
prepared in the absence of proteases inhibitors. MFAnxA1 and MFAnxA1
mutant-transfected HEK293 cell lysates (150 L) were immunoprecipi-
tated with 10 L anti–c-Myc antibody and 30 L of protein G sepharose
beads (Invitrogen), overnight at 4°C, in a final volume of 500 L of lysis
buffer. Same protocol was used to immunoprecipitated purified glutathione
S-transferase (GST)–AnxA1 and GST-SAnxA1, using 50 L glutathion
sepahrose 4B beads (Amersham Biosciences). Purified PR3 (50-200 mU;
Elastin Products) or neutrophil lysate were added to the immunoprecipi-
tated product containing intact MFAnxA1 or MFAnxA1 mutants, or
GST-AnxA1, or GST-SAnxA1. The reaction was incubated at 37°C for
30 minutes, and thereafter a mixture of protease inhibitors was added to
prevent further proteolysis. The remaining pellet was boiled in 30 L 6 
Laemmli buffer, and samples were subjected to 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis.
Recombinant protein purification. AnxA1 wild-type and SAnxA1
(super AnxA1; triple mutant A11R/V22K/V36K) were generated using
pcDNA3.1/MFA1 and pcDNA3.1/MFA1-A11R/V22K/V36K as template.
PCR (35 cycles of consisting of incubation for 1 minute at 94°C, 1 minute at
55°C, and 1 minute 20 seconds at 72°C) products were cloned into the
BamHI and XhoI sites of pGEX-6P-1 vector (GE Healthcare). BL21
Escherichia coli cells were transformed with pGEX-6P-1/AnxA1 or
pGEX-6P-1/AnxA1-A11R/V22K/V36K mutant and grown overnight at 37°C
under continues agitation (225 rpm). AnxA1 and SAnxA1 expression were
induced incubating subconfluent culture (optical density,  0.4) with 1mM
IPTG (isopropyl -D-1-thiogalactopyranoside; Promega) for an additional
6 hours at 37°C. Cell pellets from 1 L culture were lysed in 50 mL
phosphate-buffered saline (PBS) containing 0.2% NP40, 1mM DTT, 5 mg
DNase, 5 mg lysozyme and protease inhibitor cocktail (Roche) for
30 minutes, before loading onto a Glutathione Sepharose 4B column
(GSTPrep FF; GE Healthcare) using an A¨ KTAprime plus system along
manufacturer’s instruction. GST tag removal was carried out by loading
330 U PreScission protease (GE Healthcare). After overnight incubation at
4°C, recombinant proteins were eluted with phosphate buffer (140mM
NaCl, 2.7mM KCl, 10mM Na2HPO4, and 1.8mM KH2PO4) and then
dialyzed 5 times against PBS to remove any contaminant. The level of
endotoxin were measured by the E-Toxate kit (Sigma-Aldrich) according to
the manufacturer’s instruction and were below 0.1 EU/mL. Protein concen-
tration was determined using BCA protein assay kit (Pierce, Thermo Fisher
Scientific, Perbio Science UK, Ltd). Proteins were stored at 80°C in PBS
containing 5% glycerol.
In vitro analyses for bioactivity
Receptor binding assay. Receptor competition binding studies were
performed on FPR2 stably transfected HEK293 cells as previously de-
scribed.17 Briefly, W-peptide (WKYMV; Phoenix Pharma) was iodinated
on tyrosin (specific activity of 1507.17 Ci/mmol) and used as tracer. Cells
(1  106) were incubated with 1M cold W-peptide or increasing concen-
tration of AnxA1 or SAnxA1 (1nM to 30M) for 1 hour in Dulbecco PBS at
4°C. The bound and unbound tracer were separated by filtration through
Whatman GF/C glass microfiber filters using a vacuum manifold, before
-counting.
Calcium mobilization assay. FPR2-HEK 293 cells or freshly prepared
PMNs were incubated with 2M Fura 2-AM (Molecular Probes, Invitro-
gen) in Hanks balanced salt solution supplemented with 2mM CaCl2 at
37°C for 1 hour in the dark. Subsequently, cells were washed and stimulants
added at indicated concentrations. Ionomycin (1M) was used as a positive
control. Mobilization of intracellular calcium was measured by recording
the ratio of fluorescence emission at 510 nm after sequential excitation at
340 and 380 nm using the NOVostar microplate reader (BMG Labtech).
Flow chamber assay. Human umbilical vein endothelial cells
(HUVECs) were cultured until confluence and stimulated with 10 ng/mL
tumor necrosis factor- for 4 hours (Sigma-Aldrich). Isolated PMNs were
incubated with AnxA1 or SAnxA1 for 10 minutes at 37°C, before flow over
HUVEC monolayer at a rate of 1 dyn/cm2, for 8 minutes, as described.17
PMN/HUVEC interaction in the flow chamber was monitored on 6 random
fields recorded for 10 seconds. Analysis of total cell capture, rolling, and
firmly adherent PMNs was carried out off-line by manual quantification. In
some cases, cells flowed over the HUVEC monolayers were collected and
compared with resting (not-flowed) PMNs for the extent of membrane PR3
expression using a specific monoclonal antibody (ANCA anti-PR3, clone
CLB12.8; Sanquin), and standard flow cytometric protocol.
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Assessment of anti-inflammatory activity
Intravital microscopy of the mouse cremaster muscle. C57BL/6 or Fpr2
null mouse cremaster muscle microcirculation was prepared for intravital
microscopy as described previously.18 Briefly, mice were injected with
20 ng interleukin-1 (IL-1; Peprotech) intrascrotally, and 2 hours after
injection, anesthetized with a mixture of xylazine (7.5 mg/kg; Millpledge
Pharmaceuticals) and ketamine (150 mg/kg; Amersham Biosciences). The
right jugular vein was cannulated for drug administration. The testis was
exposed through a small scrotal incision. The cremaster was mounted on a
Zeiss Axioskop FS microscope and superfused with PBS at 37°C for a
30-minute stabilization period. A suitable postcapillary venule (wall shear
rate  500 per second, 20 m  diameter  40 m, length  100 m)
was selected and either vehicle (PBS-0.1% bovine serum albumin), AnxA1,
or SAnxA1 (0.6 mg/kg,  400 pmol per mouse)19 was injected via the
jugular vein and microcirculation monitored for 30 minutes. Off-line
analysis of leukocyte/endothelium interactions yielded the numbers for
leukocytes flux (number of cells passing a fix point/minute) and cell
adhesion (static cells for at least 30 seconds).
Skin edema. BALB/c mice (B&K Universal) were shaved from the
mid-dorsal region and injected intradermally with 50 L vehicle (Tyrode
solution-0.1% bovine serum albumin) or N-formyl-Met-Leu-Phe (fMLF;
100 pmol) in the absence or presence of AnxA1 or SAnxA1 (1-100 ng).
After 4 hours, mice were culled, and injection sites excised (5-mm
biopsies). Samples were then processed for the myeloperoxidase (MPO)
and PR3 activity.
Paw edema. C57BL/6 mice were lightly anesthetized and injected
intraplantarly with 50 L of 1% 	-carrageenan (Sigma-Aldrich). AnxA1
and SAnxA1 (1 g) were administered together with 	-carrageenan.
Edema, measured with a hydropletismometer (Ugo Basile), was calculated
as previously described20 by subtracting basal paw volumes.
MPO enzymatic activity. MPO activity was assessed by measuring the
H2O2-dependent oxidation of 3,3
,5,5
-tetramethylbenzidine (0.05% wt/vol
TMB-12.5% dimethyl sulfoxide) using skin and paw tissue samples,
following a detailed protocol previously reported.20 Assays were performed
in triplicates and normalized for protein content.
Histology. Histologic analyses were conducted on paws collected
24 hours after 	-carrageenan. Fixed (4% formalin) samples were incubated
with 0.1mM EDTA (ethylenediaminetetraacetic acid) for 14 days before
paraffin embedding. Sections (5-m) were deparaffinized and stained with
hematoxylin and eosin. A minimum of  3 sections per animal were
evaluated.
Statistical analysis
Data are expressed as mean plus or minus SEM. Student t test or analysis of
variance were used for 2 or more groups. GraphPad Prism 4.0 software
(GraphPad). In all cases, a P value .05 was taken as significant.
Results
Identification of SAnxA1
We began this study by determining the relative contribution of
each PR3 sensitive site in the AnxA1 N terminus by generating a
series of single, double, and triple mutants (Figure 1A). Site direct
mutagenesis was carried out using as template a double-tagged
AnxA1 (c-Myc on the N terminus and Flag at the C terminus;
MFAnxA1)11 allowing us to track down the clipped N terminus.
Three single (A11R; V22K; V36K), 3 double (A11R/V22K; A11R/
Figure 1. Effect of mutations in the N-terminal region of
AnxA1 on cleavage by PR3. (A) Schematic representation of
AnxA1 domains, highlighting the 3 PR3 cleavages sites in the
N-terminal region; N-terminal domain sequences of AnxA1 and
AnxA1 mutants. (B) Western blot analysis of MFAnxA1 mutants
expression in HEK293 transfected cells: lysates were immunoblot-
ted (IB) with anti–c-Myc, anti-Flag, and anti-AnxA1 antibodies.
(C) Immunoprecipitation (IP) for c-Myc products were incubated
for 30 minutes at 37°C with PR3 (50, 100, or 200 mU) and intact
MFAnxA1 recovered by immunoblotting for c-Myc. Data are
representative of 3 distinct analyses performed with distinct
preparations of lysates.
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V36K; V22K/V36K), and one triple (A11R/V22K/V36K) MFAnxA1
mutants were cloned and produced by transfection in HEK293 cells
(Figure 1B). For the in vitro AnxA1 cleavage assay, cell lysates
were immunoprecipitated with anti–c-Myc and then incubated with
increasing amount of recombinant PR3 for 30 minutes at 37°C. As
shown in Figure 1C, none of the single mutants presented any
significant difference in their cleavage by PR3, compared with the
parental protein MFAnxA1, the exception being mutant V22K,
which was modestly resistant to 100 mU PR3. Consistent with this,
the double-mutant A11R/V22K demonstrated similar partial resis-
tance to cleavage by PR3, with no further improvement being
added by the second mutation on A11R (Figure 1C). This systematic
analysis showed that the triple mutant A11R/V22K/V36K displayed
complete resistance to PR3 cleavage at all the concentrations
tested. Based on these results, further characterization of the triple
mutant, christened super AnxA1 or SAnxA1, was then performed.
Purification of recombinant AnxA1 and SAnxA1
Untagged AnxA1 and SAnxA1 were subcloned in pGEX-6P1 GST
vector to transform E coli BL21 cells, and both proteins could be
recovered from the cell lysates (Figure 2A). Highly purified
proteins were obtained using GST-purification and in-column tag
removal system as assessed by Blue Coomassie staining and
immunoblot for AnxA1 (Figure 2B). When the cleavage assay was
run with PR3, SAnxA1 was confirmed to be more resistant than
parent AnxA1 (Figure 2C). Of importance, the same held true when
PMN extracts were used as cleaving material: SAnxA1 was
approximately 5 times more resistant than AnxA1.
SAnxA1 retains AnxA1 bioactivity at FPR2
Next, we investigated whether the mutations inserted in SAnxA1
would influence its biologic activity in vitro. In the binding assay to
FPR2-HEK293 cells, incubation with AnxA1 competed with the
tracer with an apparent half maximal inhibitory concentration of
150  5nM (comparable with our previous data17); SAnxA1
retained specific binding with a half maximal inhibitory concentra-
tion of 590nM ( 4-fold lower affinity than AnxA1; Figure 3A).
This slight reduced binding affinity to FPR2 was not reflected in
SAnxA1 ability to activate FPR2 as tested by Erk phosphorylation
(Figure 3B) or Ca2 fluxes (Figure 3C) in FPR2-HEK293. The
latter readout allowed us to test SAnxA1 on isolated PMNs:
stimulation of these cells with 1 nM SAnxA1 elicited a sustained
increase in [Ca2]i (peak value  1.4) comparable with the
response obtained with AnxA1 (peak value  1.3). We next
compared the [Ca2]i maximal values obtained, using different
concentrations of AnxA1 and SAnxA1 (0.1 or 1nM) and ionomycin
as a positive control: in line with the data with FPR2-HEK (Figure
3C), no significant differences in PMNs downstream signal was
measured (Figure 3D). Next we tested whether these effects would
lead to modulation of PMN reactivity.
SAnxA1 blocks PMN interaction with endothelial cells:
indication for higher efficacy
In the flow chamber assay, SAnxA1 (10nM) produced profound
inhibition on PMN interaction with HUVEC monolayers: see
representative images in Figure 4A. Detailed analyses revealed that
both AnxA1 and SAnxA1 affected PMN capture, rolling, and
adhesion, but the latter readout was significantly more inhibited by
SAnxA1 (Figure 4B). Such an effect was concentration-dependent
and optimal at 10nM for either recombinant protein (Figure 4C).
Noteworthy, this protocol leads to partial PMN activation as
evident from cell surface PR3 expression which almost doubles in
PMNs flowed over the HUVEC monolayer; values of median
fluorescence intensity of 81  2.5 and 143  8.3 for unstimulated
and flowed PMNs, respectively, could be calculated in 4 distinct
cell preparations and experiments (P  .05).
To determine the impact of SAxnA1 (and AnxA1) on leukocyte/
endothelium interaction in vivo, the mouse cremasteric microcircu-
lation inflamed with IL-1 was used.21 Injection of the cytokine
provoked a marked inflammation with changes in both the extent of
cell flux (Figure 5A), rolling cell velocity (31  10 and
3.1  0.1 m/s, for vehicle and IL-1, respectively) and cell
adhesion (Figure 5A). Injection of either AnxA1 or SAnxA1
modified the on-going inflammation in a different way. Both
AnxA1 and SAnxA1 augmented cell velocity, with a significant
effect at  10 minutes after treatment (Figure 5B), an effect
mirrored by the reduced degree of cell adhesion (Figure 5C).
Importantly, the effect of SAnxA1 incremented over time (eg,
see cell adhesion at 30 minutes after administration;  50%
inhibition) whereas that of the natural protein peaked at the
20 minutes time point ( 30% inhibition of cell adhesion;
Figure 5C). Importantly, either recombinant protein was ineffec-
tive in animals nullified for the murine formyl-peptide receptor
2 (the ortholog of human FPR2; Figure 5D shows the data for
cell adhesion).
Figure 2. Purification of recombinant AnxA1 and SAnxA1 by
chromatography. After cloning in the pGEX-6P-1 vector, in frame
with GST, GST-tag was used to purify AnxA1 and SAnxA1 on a
Glutathione Sepharose 4B column. (A) Coomassie blue-stained
gel of recombinant GST-AnxA1 and GST-SAnxA1 expressed in
BL21 cells after IPTG treatment. (B) Coomassie blue-stained gel
of recombinant AnxA1 and SAnxA1 recovered after GST tag
removal, using PreScission Protease. Immunoblot (IB) of purified
recombinant AnxA1 and SAnxA1, using a specific anti-AnxA1
antibody. (C) Western blotting analysis of AnxA1 and SAnxA1
cleavage by recombinant PR3 and PMN lysates, after incubation
for 30 minutes at 37°C. Results are representative of 3 distinct
preparations and experiments.
ANTI-INFLAMMATORY PROPERTIES OF SUPER ANNEXIN A1 4291BLOOD, 18 NOVEMBER 2010  VOLUME 116, NUMBER 20
For personal use only.on November 7, 2017. by guest  www.bloodjournal.orgFrom 
SAnxA1 shows increased and prolonged anti-inflammatory
activity
Next, we established if SAnxA1 and AnxA1 displayed anti-
inflammatory activities with a different profile, applying in more
complex models of inflammation, where PMN activation and
recruitment is the end point of multiple processes. Intradermal
injection of fMLF provoked marked PMN accumulation that could
be reliably quantified by MPO activity: 180  30 and 350  44 mU
MPO/mg tissue for vehicle- and fMLF-treated skin sites, respec-
tively. Coadministration of AnxA1 or SAnxA1 (1-100 ng equiva-
lent to 0.24-24 pmol/site) inhibited the cellular response to fMLF,
with the mutant protein affording significantly higher degree of
inhibition (Figure 6A).
To study SAnxA1 biologic properties over a longer time-frame,
the mouse paw edema model was used.20 Intra-paw injection of
	-carrageenan provokes a marked localized inflammatory response
that peaks early on (2 hours) as well as at later time points (24 hours
after injection; Figure 6B). Coinjection of AnxA1 or SAnxA1
induced a mild but yet significant inhibition of paw edema (47%
and 30%, respectively) at 4 hours. Conversely, as the edema
progressed to the second peak, only the SAnxA1 displayed
significant inhibitory properties ( 30%; Figure 6B). These macro-
scopic measurements were corroborated by histologic analyses,
whereby reduced infiltration of inflammatory leukocytes could be
seen in both AnxA1- and SAnxA1-treated paw section (4-hour time
point; Figure 6C) whereas low numbers of cells at 24 hours after
	-carrageenan could be observed only in the SAnxA1 group
(Figure 6C). Finally, biochemical determination of MPO activity in
24 hours paw extracts revealed 5500  200 versus 2200  100 mU/
mg tissue, for vehicle- and SAnxA1-treated paws, respectively
(P  .001, 6 mice per group).
Discussion
In this study we report generation and characterization of an
AnxA1 mutant able to resist to PR3 (and other proteases present on
PMN extracts) cleavage. SAnxA1 displays exquisite anti-PMN
properties both in vitro and in vivo, with particular efficacy on
PMN interaction with inflamed endothelia. These data demonstrate
that AnxA1 cleavage (at least the one effected by serine proteases)
is not a prerequisite for biologic efficacy but rather a catabolic
event, as originally hypothesized.4,11
One of the hallmarks of PMN activation is release of protein-
ases such as cathepsin G, elastase, and PR3.22 These potent biologic
weapons help neutrophils to transmigrate across the endothelial
Figure 3. SAnxA1 binds and activates human FPR2.
(A) Analysis of competition binding in FPR2-HEK293 cells using
AnxA1 and SAnxA1 to compete with the tracer (W peptide;
82pM). Representative of 2 experiments in triplicate. (B) FPR2-
HEK293 cells were incubated with 1nM AnxA1 and SAnxA1, for
the indicated times, to determine the level of Erk1/2 phosphoryla-
tion by Western blot using anti–p-Erk1/2 antibody. The bar graph
reports the densitometric analysis of the p-Erk2 bands shown on
the left. Representative of 3 experiments. Calcium mobilization in
(C) FPR2-HEK293 cells and (D) isolated PMNs. In all cases,
cells were loaded with 2M Fura-2 and analyzed for [Ca2]i
changes after 0.1-1nM AnxA1 or SAnxA1. Fluorescence ratios
tracing of representative experiment recorded in a dual excita-
tion fluorescent spectrophotometer are shown (left panels).
Maximal intracellular calcium increased induced by different
concentration of AnxA1 or SAnxA1 (0.1 or 1nM) were normal-
ized to the response induced by ionomycin (1M; taken as
100%; right panels). Values are expressed as the mean SEM
of 3 independent experiments.
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wall23 as well as to fight pathogens,24 facilitating disposal of
potentially harmful products released during inflammation and
infections.25,26 However, current view on the role of these protein-
ases in PMN biology suggest more than protein-degrading en-
zymes so that they can affect several pathophysiologic signaling
pathways.27 For instance, studies have shown that release of PR3
and human neutrophil elastase (HNE) from activated PMNs can
result in their entry into endothelial cells where they can directly
cleave p65 subunit of nuclear factor-B in the N- and C-terminal
region, respectively,28 affecting cytokine synthesis.25,29
Our interest on these enzymes stems from the observation that
cleaved AnxA1 is released/detected in the supernatant of activated
PMNs5 as well as in neutrophilic inflammatory exudates.14,15
Restricting our attention to the microenvironment of an activated
PMNs, we found a pivotal role for PR3 in cleaving endogenous
AnxA1,11 thus providing another example of contribution of these
proteinases to the modulation of signaling pathways. Matrix-
assisted laser desorption/ionization time-of-flight analysis of the
peptides originated from AnxA1 treatment with PR3 or PMN
membrane fractions allowed us to single out 3 potential cleavage
recognition sites located at A11, V22, and V36 (see 11). In our
experimental settings, PR3 cleavage of AnxA1 N terminus can
occur at all 3 sites; congruently, SAnxA1 was highly resistant to
proteolysis by recombinant PR3 and PMN extracts.
The identification of an uncleavable form of AnxA1 allow us to
address a fundamental question in the biology of AnxA1, and
possibly other Annexins10,30: whether cleavage of the N terminus is
an activating process leading to the release of the bioactive core of
the protein or a catabolic event terminating its action. In resting
PMNs, AnxA1 resides in the gelatinase granules and is rapidly
exported on the cells surface upon cell stimulation,31 to modulate
the extent of PMN adhesion and emigration, often promoting cell
detachment.7,17,19 Once at the site of inflammation, de novo AnxA1
synthesis occurs, likely to modulate PMN apoptosis and phagocy-
tosis by resident macrophages as well as instruct T cells toward
activation and expansion (for review see4,32). Most of these effects
of AnxA1 are conveyed by specific receptors, namely FPR2,33 as
demonstrated for antiadhesive7 and apoptotic9 actions, though
intriguingly, a recent study indicated the central core of AnxA1
(amino acids 47-346) as responsible for the recognition of apopto-
tic Jurkat cells by phagocytes,34 suggesting different biologic
functions between the N terminus and the main core of this protein.
Once SAnxA1 was generated and validated, it was important to
test that the mutations had not modified fundamental structural and
functional characteristics of the protein. Binding to FPR2 was
tested and retained, although with an apparent reduction in affinity.
It should be noted that, in line with what argued for the native
protein,17 use of short peptides as tracers (because AnxA1 cannot
be radioiodinated without loss of activity) may lead to underesti-
mate its affinity to this receptor. Indeed, the same apparent
discrepancy was reported in our previous study with recombinant
AnxA1.17 In these experiments, both AnxA1 and SAnxA1 were
able to activate FPR2-downstream responses at concentrations
much lower (0.1-1nM) than those required to displace radiolabeled
W peptide.
In a separate study, the effects of 6 FPR peptides were tested on
actin polymerization and oxidant production in human PMNs;
although all ligands showed similar efficacy for both responses,35
their potencies/affinities varied over 3 and 4 orders of magnitude
for actin polymerization and oxidant production, respectively. Such
an effect has been explained in terms of selective stabilization of
different active receptor states and by the fact that the kinetic
lifetimes of particular ligand-receptor complexes play an important
role in determining signaling outcomes. In other words, different
ligands may produce not only different numbers but also different
lifetimes of receptor states relevant to production of a given
response.
Whereas there was no major difference between AnxA1 and
SAnxA1 in eliciting postreceptor events, some degree of distinc-
tions emerged when PMN reactivity on inflamed endothelia was
analyzed. Indeed, it is highly likely (and in part we could
demonstrate it in the flow assay) that PR3 can be rapidly activated
on the PMN cell surface in these experimental conditions.36,37
Preincubated with isolated PMNs, SAnxA1 could produce signifi-
cant inhibition of their reactivity with the HUVEC monolayer, with
higher efficacy than the parent protein on the extent of PMN
adhesion. Such an effect is highly likely to occur via FPR2,17
however we cannot exclude that mutations in SAnxA1 might have
not altered ability to bind other members of this receptor family, in
line with data generated with N-terminal–derived peptides.38,39
Indeed, SAnxA1 affected PMN rolling by  50%, an effect
displayed by short N-terminal peptides and proposed to stem from
FPR1 activation.17 Irrespective of the molecular target, these
Figure 4. SAnxA1 inhibits PMN interaction with HUVECs. (A) Representative
images of the flow chamber assay. Isolated PMNs were incubated with 10nM SAnxA1
for 10 minutes before flow over tumor necrosis factor-stimulated HUVEC monolay-
ers. (B) Cumulative data for PMN capture, rolling, and adhesion after incubation with
10nM AnxA1 or SAnxA1 and flow over the HUVECs. (C) Concentration response for
AnxA1 and SAnxA1 on the extent of PMN adhesion to HUVECs under flow. Data are
mean  SEM of 3 experiments performed with distinct donor cells. *P  .01 versus
vehicle (as calculated on original values) and #P  .05 versus respective AnxA1
dataset.
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molecular and functional experiments encouraged us to test
SAnxA1 in more stringent experimental settings. To this end,
analysis of the inflamed microvasculature was conducted. In fact,
previous studies revealed potent inhibitory properties of AnxA1
and peptides derived from the N-terminal region19 with antiadhe-
sive properties likely to occur via activation of the FPR2 or-
tholog.7,40 Moreover, cell recruitment to the postcapillary venule
endothelium is under tonic inhibitory control of endogenous
AnxA1.18 After inflammation of the microcirculation with IL-1,
reduction in the extent of cell flux (associated with proper rolling
phenomenon, ie, low cell velocity on the endothelium) was
complemented with increased in cell adhesion. Whereas an anti-
inflammatory dose of AnxA119 did not affect IL-1–induced
modifications in cell rolling, SAnxA1 brought this process back to
the values measured in vehicle-treated mice. Another striking
difference was seen with respect to cell adhesion again with
SAnxA1 displaying prolonged inhibitory properties. We could not
determine the activation/involvement of PR3 (and other serine
proteases, for that matter) in these microvascular events but in
analogy to the flow chamber study with isolated PMNs, we
hypothesize that leukocyte rolling and adhesion is a sufficient
stimulus to activate PR3. Indeed, serine proteases have a function
on the process of cell adhesion and emigration, with most studies
addressing the potential of elastase,26,29,41 because of their expres-
sion on the cell surface of the adherent and migrating leukocyte.42
Using the recently described Fpr2 null mouse colony,40 we could
demonstrate that the inhibitory effects of SAnxA1, and indeed
AnxA1, relied entirely on this specific receptor.
In any case, these results suggest that reducing AnxA1 cleavage
greatly influences the ability of this homeostatic mediator to affect
PMN adhesion to inflamed endothelial cells. This amelioration is
reflected by SAnxA1 potency and, more importantly, time-
dependency compared with naive AnxA1, highlighting a unique
aspect of the anti-inflammatory properties of AnxA1. We propose a
model whereby a counter-regulatory function of AnxA1 on PMN
adhesion is modulated by the coordinated action of PR3: all this
would satisfy a homeostatic function to regulate the extent of PMN
trafficking in acute vascular inflammation.
In final part of the study, we determined the anti-inflammatory
potential of SAnxA1 in the context of more severe inflammatory
settings. In the fMLF-induced skin model, extravasated PMNs
remain trapped at the inflammatory site creating a localized pool of
serine proteases and other enzymes. It was reassuring to observe
that as low as 27 fmol SAnxA1 delivered locally to the site of
inflammatory insult provoked marked ( 60%) attenuation of the
MPO activity detected, with a doubling/trebling efficacy over
natural AnxA1. Another predicted characteristic of SAnxA1 would
be a longer lasting effect, a hint for which emerged in the
experiments of intravital microscopy. To expand on this hypothesis,
we tested the properties of the 2 recombinant proteins in the mouse
paw edema model20 characterized by an early phase and a delayed
phase of inflammation. We chose the local route of administration
to increase the exposure of the proteins to PR3 and other
proteolytic enzymes carried to the site of inflammation by the
migrating PMNs. Whereas both AnxA1 and SAnxA1 inhibited,
with no apparent difference, the early response at time 4 hours, only
Figure 5. Longer lasting effect of SAnxA1 on leukocyte
adhesion in postcapillary venules. Mice were injected intrascro-
tally with either saline or 50 ng IL-1, and the extent of leukocyte
rolling and adhesion was quantified 3 hours later. Image is
representative of the inflammatory status induced by the cytokine.
Data are mean  SEM of 6 mice per group. *P  .01 versus
vehicle. Mice pretreated with IL-1were instrumented an adminis-
tered via the jugular vein with PBS, AnxA1 (0.6 mg/kg), or
SAnxA1 (0.6 mg/kg), and the microcirculation monitored for
further 30 minutes both for cell rolling velocity (B) and cell
adhesion (C). Values are mean  SEM of 5 mice per group.
*P  .01 versus vehicle group and #P  .05 versus respective
AnxA1 group. (D) FPR2 null mice were treated with IL-1 and
recombinant proteins as described in panels B-C. Values are
mean SEM of 5 mice per group.
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SAnxA1 was effective on the marked inflammation measured
24-hours after 	-carrageenan. These results do not allow us to
dissect the mechanism(s) behind this long lasting effect, apart from
proposing resistance to cleavage hence longer presence at the
inflammatory site. We cannot exclude the involvement of other
pathways in the striking effect of SAnxA1, persisting within the
inflamed paw, on the 24-hour edema, including promotion of
retrograde leukocyte transmigration43,44 and/or removal of apopto-
tic leukocytes.9 In any case, we observed major reductions in
immune cell infiltrates in the 24-hours after 	-carrageenan. Tissue
samples of mice treated with SAnxA1 was observed by histology
and quantified by MPO activity.
We believe the novel findings here presented open up 2 important
considerations. First, that pathologic conditions characterized by
increased membrane expression of PR3 could lead to potential
harmful effects because of a misbalanced action of this catabolic
enzyme on the homeostatic action of the endogenous AnxA1
pathway. Such an example could be the Wegener granulomatosis: a
form of small-vessel vasculitis characterized by primed PMNs
flowing in the bloodstream.45 Second, agents targeting directly or
indirectly the PR3/AnxA1 pathway could be a valid novel therapeu-
tic strategy to disentangle trapped PMNs from inflamed microvas-
culature in these diseases. Consistent with this, it is important to
note that glucocorticoids, potent anti-inflammatory drugs used in
different types of vasculitis including Wegener granulomatosis,
positively modulate AnxA1 expression and release in PMNs46 and
can also up-regulate the receptors for this mediator.47-49 We propose
treatment of small (and possibly large) vessel vasculitides with
glucocorticoids would increase the rate of expression and/or
release of AnxA1, thus counteracting the increased catabolism that
would be occurring on the PMN cell surface.
In conclusion, we have unveiled a novel piece in the complex
puzzle of the PMN AnxA1 biologic system. These findings may be
beneficial for the design of inhibitors aimed at neutralizing the
cleavage activity of PR3 toward endogenous AnxA1, representing
a possible avenue for novel therapeutic discovery programs.
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Figure 6. SAnxA1 displays longer-lasting inhibitory effects on PMN recruitment
and inflammation in vivo. (A) Mice were treated intradermally with fMLF (100 pmol)
and the reported doses of AnxA1 and SAnxA1. Four hours later, skin samples (5-mm
biopsies) were harvested and assayed for MPO activity. MPO activity values in
fMLF-treated skin sites were 350  44 mU/mg of tissue (taken as 100% control).
Data are mean  SEM of 4 separate experiments with 3-7 mice/group. (B) Time
course of 	-carrageenan-induced paw edema in mice locally treated with PBS
(50 L), AnxA1 (1 g), or SAnxA1 (1 g). Values are mean  SEM of 3 separate
experiments with n  6 mice per group. Representative images of the paw collected
24 hours after treatment. *P  .05 vs. vehicle group and #P  .05 versus respective
AnxA1 group. (C) Hematoxylin and eosin staining of paw tissue samples collected
4 and 24 hours after 	-carrageenan in mice treated with either vehicle, AnxA1, or
SAnxA1 as in panel B. Images are representative of analyses of tissue samples from
4 mice.
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